Pure antiestrogens: The most important advance in the endocrine therapy of breast cancer since 1896?

Annals of the New York Academy of Sciences

Volumn 784, Issue , 1996, Pages 325-335

  Nicholson, R I ^a   Gee, J M W ^a   Bryant, S ^a   Francis, A B ^a   McClelland, R A ^a   Knowlden, J ^a   Wakeling, A E ^b   Osborne, C K ^c  

^a CARDIFF UNIVERSITY   (United Kingdom)

^b ASTRAZENECA   (United Kingdom)

^c UNIVERSITY OF TEXAS HEALTH SCIENCE CENTER AT SAN ANTONIO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ANTIESTROGEN; FULVESTRANT; N BUTYL 11 (3,17BETA DIHYDROXYESTRA 1,3,5(10) TRIEN 7ALPHA YL) N METHYLUNDECANAMIDE; TAMOXIFEN; ANTINEOPLASTIC HORMONE AGONISTS AND ANTAGONISTS;

ANTINEOPLASTIC ACTIVITY; BREAST CANCER; CELL STRAIN MCF 7; CONFERENCE PAPER; DRUG SAFETY; HISTORY OF MEDICINE; HORMONAL THERAPY; HUMAN; HUMAN CELL; BREAST TUMOR; CLINICAL TRIAL; COMPARATIVE STUDY; FEMALE; ISOLATION AND PURIFICATION; REVIEW;

ANTINEOPLASTIC AGENTS, HORMONAL; BREAST NEOPLASMS; CLINICAL TRIALS; ESTROGEN ANTAGONISTS; FEMALE; HUMANS;

EID: 0030606494     PISSN: 00778923     EISSN: None     Source Type: Book Series    
DOI: 10.1111/j.1749-6632.1996.tb16247.x     Document Type: Article

References (60)

1. WAKELING, A. E. 1993. The future of pure antiestrogens in clinical breast cancer. Breast Cancer Res. Treat. 25: 1-9.
2. NICHOLSON, R. I., A. B. FRANCIS, D. L. MANNING & J. M. W. GEE. 1994. Pure antiestrogens (ICI 164384 and ICI 182780) and breast cancer: is the attainment of complete estrogen withdrawal worthwhile? Endocr. Related Cancer 1: 5-17.
3. WILSON, A. P. M., P. J. WEATHERILL, R. I. NICHOLSON, P. DAVIES & A. E. WAKELING. 1990. A comparative study of the interaction of estradiol and the steroidal pure antiestrogen, ICI 164384, with molybdate stabilized estrogen receptor. J. Steroid Biochem. 35: 421-428.
4. WAKELING, A. E. & J. BOWLER. 1987. Steroidal pure antiestrogens. J. Endocrinol. 112: R7-R10.
5. NICHOLSON, R. I., J. M. W. GEE, C. L. EATON, D. L. MANNING, R. E. MANSEL, A. K. SHARMA, A. DOUGLAS-JONES, M. PRICE-THOMAS, A. HOWELL, D. L. DEFRIEND, N. J. BUNDRED, E. ANDERSON, J. F. R. ROBERTSON, R. W. BLAMEY, M. DOWSETT, P. WALTON & A. E. WAKELING. 1994. Pure antiestrogens in breast cancer: experimental and clinical observations. In Sex Hormones and Antihormones in Endocrine Dependent Pathology: Basic and Clinical Aspects. M. Motta & M. Serio, Eds.: 347-360. Medica/Elsevier. Amsterdam/New York.
6. DEFRIEND, D. L., A. HOWELL, R. I. NICHOLSON, E. ANDERSON, M. DOWSETT, R. E. MANSEL, R. W. BLAMEY, N. J. BUNDRED, J. R. ROBERTSON, C. SAUNDERS, M. BAUM, P. WALTON, F. SUTCLIFFE & A. E. WAKELING. 1994. Investigation of a new pure antiestrogen (ICI 182780) in women with primary breast cancer. Cancer Res. 54: 408-414.
7. HOWELL, A., D. L. DEFRIEND, R. W. BLAMEY, J. F. ROBERTSON & P. WALTON. 1995. Response to a pure antioestrogen (ZM 182780) in tamoxifen-resistant breast cancer. Lancet 345: 29-30.
8. MUSGROVE, E. A., A. E. WAKELING & R. L. SUTHERLAND. 1989. Points of action of estrogen antagonists and a calmodulin antagonist within the MCF-7 human breast cancer cell cycle. Cancer Res. 49: 2398-2404.
9. WAKELING, A. E., E. NEWBOULT & S. W. PETERS. 1989. Effects of antiestrogens on the proliferation of MCF-7 human breast cancer cells. J. Mol. Endocrinol. 2: 225-234.
10. NICHOLSON, R. I., K. J. WALKER, N. BOUZUBAR, R. WILLS, J. M. W. GEE, N. K. RUSHMERE & P. DAVIES. 1990. Estrogen deprivation in breast cancer: clinical, experimental, and biological aspects. Ann. N.Y. Acad. Sci. 595: 316-327.
11. WISEMAN, L. R., A. E. WAKELING, F. E. MAY & B. R. WESTLEY. 1989. Effects of the antiestrogen, ICI 164384, on estrogen-induced mRNAs in MCF-7 cells. J. Steroid Biochem. 31: 1-6.
12. LYKKESFELDT, A. E. & E. K. SORENSEN. 1992. Effect of oestrogen and antioestrogens on cell proliferation and synthesis of secreted proteins in the human breast cancer cell line MCF-7 and a tamoxifen-resistant variant subline, AL-1. Acta Oncol. 31: 131-138.
13. R-1. Cancer Res. 54: 1587-1595.
14. MANNING, D. L., R. A. MCCLELLAND, S. BRYANT, J. KNOWLDEN, J. M. W. GEE, A. B. FRANCIS, J. F. R. ROBERTSON, R. W. BLAMEY, R. L. SUTHERLAND, C. J. ORMANDY, R. E. MANSEL & R. I. NICHOLSON. 1995. Oestrogen-regulated genes in breast cancer: role in prognosis and endocrine sensitivity. Acta Oncol. 34: 641-646.
15. MANNING, D. L. & R. I. NICHOLSON. 1993. Isolation of pMGT1: agene that is repressed by estrogen and increased by antiestrogens and antiprogestins. Eur. J. Cancer 29A: 759-762.
16. BATES, S. E., N. E. DAVIDSON, E. V. VALVERIUS, C. E. FRETER, R. B. DICKSON, J. P. TAM, J. E. KUDLOW, M. E. LIPPMAN & D. S. SOLOMON. 1988. Expression of transforming growth factor alpha and its messenger ribonucleic acid in human breast cancer: its regulation by estradiol and its possible functional significance. Mol. Endocrinol. 2: 543-555.
17. GEE, J. M. W., J. F. R. ROBERTSON, H. B. HOYLE, S. R. KYME, R. A. MCCLELLAND, I. O. ELLIS, R. W. BLAMEY & R. I. NICHOLSON. 1994. Immunocytochemical localization of BCL-2 protein in human breast cancer and its relationship to a series of prognostic markers and response to endocrine therapy. Int. J. Cancer 59: 619-628.
18. WAKELING, A. E. & J. BOWLER. 1988. Novel antiestrogens without partial agonistic activity. J. Steroid Biochem. 30: 645-653.
19. WAKELING, A. E., M. DUKES & J. BOWLER. 1991. A potent specific pure antiestrogen with clinical potential. Cancer Res. 51: 3867-3873.
20. NICHOLSON, R. I. 1992. Pure antioestrogens and breast cancer. In Current Directions in Cancer Chemotherapy. IBC Technical Services. London.
21. GIBSON, M. K., L. A. NEMMERS, L. A. BECKMAN, W. C. BECKMAN, V. L. DAVIS, S. W. CURTIS & K. S. KORACH. 1991. The mechanism of ICI 164384 antiestrogenicity involves rapid loss of estrogen receptor in uterine tissue. Endocrinology 129: 2000-2010.
22. DAUVOIS, S., P. S. DANIELIAN, R. WHITE & M. G. PARKER. 1992. Antiestrogen ICI 164384 reduces cellular estrogen receptor content by increasing its turnover. Proc. Natl. Acad. Sci. U.S.A. 89: 4037-4041.
23. FAWELL, S. E., R. WHITE, S. HOARE, M. SYDENHAM, M. PAGE & M. G. PARKER. 1990. Inhibition of estrogen receptor-DNA binding by the pure antiestrogen ICI 164384 appears to be mediated by impaired receptor dimerization. Proc. Natl. Acad. Sci. U.S.A. 87: 6883-6887.
24. ECKERT, R. L., A. MULLICK, E. A. RORKE & B. S. KATZENELLENBOGEN. 1984. Estrogen receptor synthesis and turnover in MCF-7 breast cancer cells measured by a density shift technique. Endocrinology 114: 629-637.
25. PASQUALINI, J. R., B. SCHATZ, C. VARIN & B. L. NGUYEN. 1992. Recent data on estrogen sulfatases and sulfotransferases activities in human breast cancer. J. Steroid Biochem. Mol. Biol. 41: 323-329.
26. SANTNER, S. J., B. OHLSSON-WILHELM & R. J. SANTEN. 1993. Estrone sulfate promotes human breast cancer cell replication and nuclear uptake of estradiol in MCF-7 cell cultures. Int. J. Cancer 54: 119-124.
27. HOWARTH, N. M., A. PUROHIT, M. J. REED & B. V. L. POTTER. 1994. Estrone sulfamates: potential inhibitors of estrone sulfatase with therapeutic potential. J. Med. Chem. 37: 219-221.
28. CHETRITE, G., C. VARIN, L. DELALONDE & J. R. PASQUALINI. 1993. Effect of promegestone, tamoxifen, 4-hydroxytamoxifen, and ICI 164384 on the estrone sulfatase activity of human breast cancer cells. Anticancer Res. 13: 931-934.
29. STEWART, A. J., M. D. JOHNSON, F. E. B. MAY & B. R. WESTLEY. 1990. Role of insulin-like growth factors and type I insulin-like growth factor receptor in the estrogen-stimulated proliferation of human breast cancer cells. J. Biol. Chem. 265: 21172-21178.
30. STEWART, A. J., B. R. WESTLEY & F. E. B. MAY. 1992. Modulation of proliferative response of breast cancer cells to growth factors by oestrogen. Br. J. Cancer 66: 640-648.
31. WESTLEY, B. R. & F. E. B. MAY. 1991. IGFs and control of cell proliferation in breast and other cancers. Rev. Endocr. Related Cancer 39: 29-34.
32. IGNAR-TROWBRIDGE, D. M., K. G. NELSON, M. C. BIDWELL, S. W. CURTIS, T. F. WASHBURN, J. A. MCLACHLAN & K. S. KORACH. 1992. Coupling of dual signalling pathways: epidermal growth factor action involves the estrogen receptor. Proc. Natl. Acad. Sci. U.S.A. 89: 4658-4662.
33. WAKELING, A. E. 1994. Inhibition of EGF-receptor tyrosine kinase activity by 4-aniloquinazolines. Br. J. Cancer 69: 18 (supplement XXI, abstract 6.6).
34. NICHOLSON, R. I., J. M. W. GEE, D. L. MANNING, A. E. WAKELING & B. S. KATZENELLENBOGEN. 1995. Responses to pure antiestrogens (ICI 164384, ICI 182780) in estrogen sensitive and resistant experimental and clinical breast cancer. Ann. N.Y. Acad. Sci. 761: 148-163.
35. REDDY, K. B., G. L. MANGOLD, A. K. TANDON, T. YONEDA, G. R. MUNDY, A. ZILBERSTEIN & C. K. OSBORNE. 1992. Inhibition of breast cancer cell growth in vitro by a tyrosine kinase inhibitor. Cancer Res. 52: 3636-3641.
36. POWER, R. F., S. K. MANI, J. CODINA, O. M. CONNELLY & B. W. O'MALLEY. 1991. Dopaminergic and ligand-independent activation of steroid hormone receptors. Science 254: 1636-1639.
37. PHILIPS, A., D. CHALBOS & H. ROCHEFORT. 1993. Estradiol increases and antiestrogens antagonize the growth factor-induced activator protein-1 activity in MCF-7 breast cancer cells without affecting c-fos and c-jun synthesis. J. Biol. Chem. 268: 14103-14108.
38. OSBORNE, C. K., E. B. CORONADO & J. P. ROBINSON. 1987. Human breast cancer in the athymic mouse: cytostatic effects of long-term antiestrogen therapy. Eur. J. Cancer Clin. Oncol. 23: 1189-1196.
39. OSBORNE, C. K., M. JARMAN, R. MCCAGUE, E. B. CORONADO, S. G. HILSENBECK & A. E. WAKELING. 1994. The importance of tamoxifen metabolism in tamoxifen-stimulated growth. Cancer Chemother. Pharmacol. 34: 89-95.
40. GOTTARDIS, M. M. & V. C. JORDAN. 1988. Development of tamoxifen-stimulated growth of MCF-7 tumors in athymic mice after long-term antiestrogen administration. Cancer Res. 48: 5183-5187.
41. CLARKE, R., N. BRUNNER, B. S. KATZENELLENBOGEN, E. W. THOMPSON, M. J. NORMAN, C. KOPPI, S. PAIK, M. E. LIPPMAN & R. B. DICKSON. 1989. Progression of breast cancer cells from hormone-dependent to hormone-independent growth both in vitro and in vivo. Proc. Natl. Acad. Sci. U.S.A. 86: 3649-3653.
42. GRAHAM, M. L., J. A. SMITH, P. B. JEWETT & K. B. HORWITZ. 1992. Heterogeneity of progesterone receptor content and remodelling by tamoxifen characterize subpopulations of cultured human breast cancer cells: analysis by quantitative dual parameter flow cytometry. Cancer Res. 52: 593-602.
43. BRUNNER, N., B. BOYSEN, J. F. KIILGAARD, T. L. FRANDSEN, S. JIRUS & R. CLARKE. 1993. Resistance to 4OH-tamoxifen does not confer resistance to the steroidal antiestrogen ICI 182780, while acquired resistance to ICI 182780 results in cross-resistance to 4OH-tamoxifen. Breast Cancer Res. Treat. 27: 135 (abstract 19).
44. BRONZERT, D. A., G. L. GREENE & M. E. LIPPMAN. 1985. Selection and characterization of breast cancer cell line resistant to the antiestrogen LY 117018. Endocrinology 117: 1409-1417.
45. CLARKE, R., E. W. THOMPSON, F. LEONESSA, J. LIPPMAN, M. MCGARVEY, T. L. FRANDSEN & N. BRUNNER. 1993. Hormone resistance, invasiveness, and metastatic potential in breast cancer. Breast Cancer Res. Treat. 24: 227-239.
46. GOTTARDIS, M. M., S-Y. JIANG, M-H. JENG & V. C. JORDAN. 1989. Inhibition of taraoxifen-stimulated growth of an MCF-7 tumor variant in athymic mice by novel steroidal antiestrogens. Cancer Res. 49: 4090-4093.
47. OSBORNE, C. K., E. B. CORONADO-HEINSOHN, B. L. MCCUE, A. E. WAKELING & R. I. NICHOLSON. 1995. Comparison of the effects of a steroidal antiestrogen with those of tamoxifen in a model of human breast cancer. J. Natl. Cancer Inst. In press.
48. REECE, J. C. & B. S. KATZENELLENBOGEN. 1992. Examination of the DNA-binding ability of ER in whole cells: implications for hormone-independent transactivation and the actions of antiestrogens. Mol. Cell. Biol. 12: 4531-4538.
49. KATZENELLENBOGEN, B. S., K. L. KENDRA, M. J. NORMAN & Y. BERRTHOIS. 1987. Proliferation, hormonal responsiveness, and estrogen receptor content of MCF-7 human breast cancer cells grown in the short-term and long-term absence of estrogens. Cancer Res. 47: 4355-4360.
50. CHO, H., P. A. NG & B. S. KATZENELLENBOGEN. 1991. Differential regulation of gene expression by estrogen in estrogen growth-independent and -dependent MCF-7 human breast cancer cell sublines. Mol. Endocrinol. 5: 1323-1330.
51. NICHOLSON, R. I., A. B. FRANCIS, J. M. W. GEE, D. L. MANNING, A. E. WAKELING & B. S. KATZENELLENBOGEN. 1995. Observations arising from the use of pure antiestrogens on estrogen-responsive (MCF-7) and estrogen growth-independent (K3) human breast cancer cells. Endocr. Related Cancer 2: 115-121.
52. NUNEZ, A., M. BERRY, J. L. IMLER & P. CHAMBON. 1989. The 5′-flanking region of the pS2 gene contains a complex enhancer region responsive to estrogens, epidermal growth factor, a tumor promoter (TPA), the c-Ha-ras oncoprotein, and the c-jun protein. EMBO J. 8: 823-829.
53. NICHOLSON, R. I., R. A. MCCLELLAND, J. M. W. GEE, D. L. MANNING, P. CANNON, J. F. R. ROBERTSON, I. O. ELLIS & R. W. BLAMEY. 1994. Epidermal growth factor expression in breast cancer: association with responses to endocrine therapy. Breast Cancer Res. Treat. 29: 117-125.
54. DAVIDSON, N. E., E. P. GELMANN, M. E. LIPPMAN & R. B. DICKSON. 1987. Epidermal growth factor receptor gene expression in estrogen receptor positive and negative human breast cancer cell lines. Mol. Endocrinol. 1: 216-223.
55. HOWELL, A., D. J. DODWELL, I. LAIDLAW, H. ANDERSON & E. ANDERSON. 1990. Tamoxifen as an agonist for metastatic breast cancer. In Endocrine Therapy of Breast Cancer IV. A. Goldhirsch, Ed.: 49-58. Springer-Verlag. Berlin/New York.
56. HOWELL, A., D. J. DODWELL, H. ANDERSON & J. REDFORD. 1992. Response after withdrawal of tamoxifen and progestins in advanced breast cancer. Ann. Oncol. 3: 611-617.
57. WILSON, A. J. 1983. Response in breast cancer to a second hormonal therapy. Rev. Endocr. Related Cancer 14: 5-11.
58. VOGEL, C. L., I. SHEMANO, J. SCHOENFELDER, P. A. GAMS & M. R. GREEN. 1993. Multicenter phase II efficacy trial of toremifene in tamoxifen-refractory patients with advanced breast cancer. J. Clin. Oncol. 11: 345-350.
59. NICHOLSON, R. I. 1993. Recent advances in the antihormonal therapy of breast cancer. Curr. Opin. Invest. Drugs 2: 1259-1268.
60. NICHOLSON, R. I., D. L. MANNING & J. M. W. GEE. 1993. New antihormonal approaches to breast cancer therapy. Drugs Today 29: 363-372.